Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio

February 20, 2020

Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.